奈达铂联合依托泊苷治疗初发性小细胞肺癌的临床疗效分析

Analysis of clinical efficacy of nedaplatin combined with etoposide in the treatment of primary small cell lung cancer

目的探讨奈达铂联合依托泊苷治疗初发性小细胞肺癌的临床疗效。方法 80例初发性小细胞肺癌患者,随机分为试验组和对照组,每组40例。对照组采取顺铂联合依托泊苷治疗,试验组采取奈达铂联合依托泊苷治疗。比较两组患者临床疗效。结果试验组患者完全缓解率为30%、客观缓解率为80%;对照组患者完全缓解率为5%、客观缓解率为50%。试验组患者完全缓解率、客观缓解率均高于对照组,差异具有统计学意义(P<0.05)。结论对初发性小细胞肺癌的患者采取奈达铂联合依托泊苷治疗,临床疗效显著,值得推广。

Objective To investigate the clinical efficacy of nedaplatin combined with etoposide in the treatment of primary small cell lung cancer. Methods A total of 80 patients with primary small cell lung cancer were randomly divided into experimental group and control group, with 40 cases in each group. The control group received cisplatin and etoposide for treatment, and the experimental group received nedaplatin combined with etoposide for treatment. The clinical efficacy between the two groups was compared. Results The experimental group had complete remission rate as 30%, objective remission rate as 80%, which were 5% and 50% in the experimental group. The experimental group had higher complete remission rate and objective remission rate than the control group, and the difference was statistically significant （P〈0.05）. Conclusion Combination of nedaplatin and etoposide shows remarkable clinical efficacy in the treatment of primary small cell lung cancer, and it is worthy of promotion.